ライフサイエンスコーパス: solid organ transplantation

1 Diarrhea is a frequent complication of solid organ transplantation.

2 V) is a common opportunistic infection after solid organ transplantation.

3 mon, but challenging type of rejection after solid organ transplantation.

4 cluding those associated with bone marrow or solid organ transplantation.

5 rs, and outcomes of colectomy for CDAD after solid organ transplantation.

6 Corneal transplantation is the most common solid organ transplantation.

7 es may improve chronic CNI nephrotoxicity in solid organ transplantation.

8 ) is one of the most common infections after solid organ transplantation.

9 al trials as a potential therapy in cell and solid organ transplantation.

10 iants that seem to impact outcomes following solid organ transplantation.

11 utcome of rare PTLD subtypes in adults after solid organ transplantation.

12 ) closely follows the standard practices for solid organ transplantation.

13 ications of this novel MPS classification in solid organ transplantation.

14 to delay or prevent chronic rejection after solid organ transplantation.

15 e, is a highly desirable therapeutic goal in solid organ transplantation.

16 HL is a late complication of solid organ transplantation.

17 an exceptional finding after other types of solid organ transplantation.

18 s and outcomes associated with smoking after solid organ transplantation.

19 mmunosuppressed patients, particularly after solid organ transplantation.

20 nifest different complications compared with solid organ transplantation.

21 Allograft rejection remains the nemesis of solid organ transplantation.

22 been associated with allograft rejection in solid organ transplantation.

23 us 8 (HHV-8)-related disease described after solid organ transplantation.

24 cer is an increasing and major problem after solid organ transplantation.

25 or improved control of viral hepatitis after solid organ transplantation.

26 target this intractable problem in clinical solid organ transplantation.

27 l antibody increasingly used at induction in solid organ transplantation.

28 e smaller than other hazards associated with solid organ transplantation.

29 the context of the two most common forms of solid organ transplantation.

30 uzumab has been used in off-label studies of solid organ transplantation.

31 erm follow-up to determine its exact role in solid organ transplantation.

32 disorder (PTLD) is a serious complication of solid organ transplantation.

33 kidney dysfunction in recipients of nonrenal solid organ transplantation.

34 system participate in the immune response to solid organ transplantation.

35 ch using MRI to detect graft rejection after solid organ transplantation.

36 l as after allogeneic hematopoietic cell and solid organ transplantation.

37 established as an immunosuppressive agent in solid organ transplantation.

38 omplication after hematopoietic stem cell or solid organ transplantation.

39 lograft survival in several animal models of solid organ transplantation.

40 es mellitus (PTDM) is a common problem after solid organ transplantation.

41 s published in the last 12 months in HIV and solid organ transplantation.

42 as efficacious and safe through their use in solid organ transplantation.

43 ng the sphingosine 1-phosphate receptor 1 in solid organ transplantation.

44 and treatment of acute cellular rejection in solid organ transplantation.

45 mellitus is a common clinical problem after solid organ transplantation.

46 for the treatment of diabetes mellitus after solid organ transplantation.

47 responses in allogeneic bone marrow (BM) and solid organ transplantation.

48 reatening complications from bone marrow and solid organ transplantation.

49 on retinal complications of bone marrow and solid organ transplantation.

50 s a major complication after bone marrow and solid organ transplantation.

51 e response in a murine model of vascularized solid organ transplantation.

52 ive disorder is a well-known complication of solid organ transplantation.

53 the major cause of graft loss after clinical solid organ transplantation.

54 let transplantation and living-related donor solid organ transplantation.

55 t ramifications for clinical bone marrow and solid organ transplantation.

56 ular thrombosis is a dreaded complication in solid organ transplantation.

57 ric intensive care unit (PICU) patients with solid organ transplantation.

58 e most common cause of late graft failure in solid organ transplantation.

59 clinically desirable goal in bone marrow and solid organ transplantation.

60 future is improving long-term outcomes after solid organ transplantation.

61 Acute leukemia is rare after solid organ transplantation.

62 ve attempted to define referral criteria for solid organ transplantation.

63 utor to morbidity and mortality in pediatric solid organ transplantation.

64 serine protease inhibitor to prevent GVD in solid organ transplantation.

65 icans is extremely rare in the modern era of solid organ transplantation.

66 ith the use of chronic immunosuppression for solid organ transplantation.

67 to recipient is an uncommon complication of solid organ transplantation.

68 e T cell responses following bone marrow and solid organ transplantation.

69 e (CSA) has markedly improved the outcome of solid organ transplantation.

70 atients (mean age, 36 years) with PTLD after solid organ transplantation.

71 cipient periphery after blood transfusion or solid organ transplantation.

72 rapy, octreotide therapy, and bone marrow or solid organ transplantation.

73 t dysfunction, the major clinical problem in solid organ transplantation.

74 s an increasingly recognized complication of solid organ transplantation.

75 -mediated rejection and graft loss after all solid organ transplantation.

76 oles in the cellular and humoral response in solid organ transplantation.

77 ty (APA) is recommended in patients awaiting solid organ transplantation.

78 challenge limiting allograft survival after solid organ transplantation.

79 volved in myocardial infarction, stroke, and solid organ transplantation.

80 The incidence of cancer is increased after solid organ transplantation.

81 y a significant role in graft survival after solid organ transplantation.

82 k of cytomegalovirus (CMV) replication after solid organ transplantation.

83 is an infrequent but serious complication of solid organ transplantation.

84 lograft survival is a major challenge facing solid organ transplantation.

85 ve drugs is one of the key research goals in solid organ transplantation.

86 f peanut allergy has been reported following solid organ transplantation.

87 of hematopoiesis and to induce tolerance for solid organ transplantation.

88 munocompromised patients, particularly after solid organ transplantation.

89 dressing the organ supply/demand mismatch in solid organ transplantation.

90 (HHV) and immune control of replication post-solid organ transplantation.

91 geographic variation in CMV management after solid organ transplantation.

92 nsplantation monitoring of HLA antibodies in solid organ transplantation.

93 major cause of mortality and morbidity after solid organ transplantation.

94 ettings, it has received little attention in solid organ transplantation.

95 limus may also be associated with PRES after solid organ transplantation.

96 SC) transplantation, autoimmune disease, and solid organ transplantation.

97 een made in improving short-term outcomes in solid organ transplantation.

98 e disorder (PTLD) is a major complication of solid-organ transplantation.

99 eating pediatric with EBV (+) PTLD following solid-organ transplantation.

100 tion of a new arenavirus transmitted through solid-organ transplantation.

101 (3) children with hematopoietic stem cell or solid-organ transplantation.

102 ingle most important long-term limitation to solid-organ transplantation.

103 CKD) is a common complication after nonrenal solid-organ transplantation.

104 unization can present a special challenge to solid-organ transplantation.

105 not been thoroughly investigated in nonrenal solid-organ transplantation.

106 t transfusion support of patients undergoing solid-organ transplantation.

107 reasingly important factor in the outcome of solid-organ transplantation.

108 a significant role in the early events after solid-organ transplantation.

109 human cytomegalovirus (HCMV) infection after solid-organ transplantation.

110 n considered an absolute contraindication to solid-organ transplantation.

111 often fatal, complication of bone-marrow and solid-organ transplantation.

112 ry function, are relevant to bone-marrow and solid-organ transplantation.

113 nce in the management of rejection following solid-organ transplantation.

114 lcohol and substance abuse in the context of solid-organ transplantation.

115 TLD) is a well-recognized complication after solid-organ transplantation.

116 er lung transplantation are the lowest among solid organ transplantations.

117 ately 50%, which is far behind that of other solid organ transplantations.

118 on systems have successfully been applied in solid organ transplantations.

119 with prior coccidioidomycosis who underwent solid organ transplantation (18 liver, 24 kidney, 3 panc

120 Major underlying diseases were solid organ transplantation (24%), diabetes mellitus (22

121 er-related factors (hospital with <800 beds, solid organ transplantation activity, higher annual inci

122 As a complication of solid organ transplantation, acute graft-versus-host dis

123 ere neutropenia, hematopoietic stem cell and solid organ transplantation, advanced AIDS, and chronic

124 Pregnancy after solid organ transplantation, although considered high ri

125 International travel was common after solid organ transplantation, although the majority trave

126 ause of a complex diagnosis especially after solid organ transplantation and can lead to difficulties

127 ent a meta-analysis of clinical trials after solid organ transplantation and describe potential mecha

128 nchymal stem cells as a therapeutic agent in solid organ transplantation and emphasizes the issues (p

129 are similar to those usually reported after solid organ transplantation and have prompted different

130 ient mixed hematopoietic chimerism (MC) when solid organ transplantation and HCT are done concomitant

131 nes on the prevention and treatment of TB in solid organ transplantation and hematopoietic stem cell

132 inical application of xenotransplantation to solid organ transplantation and immune reconstitution fo

133 Belying the spectacular success of solid organ transplantation and improvements in immunosu

134 or problem for patients being considered for solid organ transplantation and in patients who require

135 injury (IRI) is an unavoidable event during solid organ transplantation and is a major contributor t

136 re remains a common complication of nonrenal solid organ transplantation and is associated with incre

137 g the periocular region represents a risk of solid organ transplantation and may produce significant

138 8 patients were identified who had undergone solid organ transplantation and subsequently underwent c

139 description of a pathogenic role for NETs in solid organ transplantation and suggest that NETs are a

140 he basis for future clinical applications of solid organ transplantation and that T-regulatory cells

141 ood and Drug Administration to be used after solid organ transplantation and to treat pemphigus vulga

142 abuse are common and may lead to a need for solid-organ transplantation and may also contribute to s

143 arity to oral calcineurin inhibitors used in solid-organ transplantation and spontaneous reporting of

144 intenance and rejection immunosuppression in solid organ transplantation, and compared with cyclospor

145 currently being realised in animal models of solid organ transplantation, and offers great hope for c

146 most prevalent infectious complication after solid organ transplantation, and recipients of isolated

147 Cancer incidence is different among solid organ transplantations, and ratios may be higher t

148 Tacrolimus has been increasingly used in solid-organ transplantation, and the effect of the drug

149 Hematopoietic cell transplantation and solid organ transplantation are definitive therapies for

150 Recipients for solid organ transplantation are growing in numbers, prog

151 ial harms of routine exercise training after solid organ transplantation are unclear.

152 tive disorders (PTLDs) that occur late after solid-organ transplantation are usually a monoclonal pro

153 re remains one of the most challenging among solid organ transplantation as a result of the high rate

154 Partial T cell depletion is used in solid organ transplantation as a valuable strategy of pe

155 t CMV infection is a serious complication of solid organ transplantation associated with more episode

156 tients with coccidioidomycosis who underwent solid organ transplantation at our center to identify fa

157 s with previous coccidioidomycosis underwent solid organ transplantation at our institution.

158 trials, including those for bone marrow and solid organ transplantation, autoimmune diseases, and ti

159 payors in reimbursing transplant centers for solid organ transplantation, based on criteria for accep

160 nexplained alteration of mental status after solid organ transplantation be evaluated for hyperammone

161 hematopoietic stem cell transplantation, or solid organ transplantation be screened for active or pr

162 As solid organ transplantation becomes increasingly common

163 A total of 3489 patients underwent solid organ transplantation between 1990 and 2008.

164 published with subject headings relating to solid organ transplantation between August 1, 2011, and

165 steroids are standard immunosuppressants in solid organ transplantation, but (long-term) side effect

166 donor bone marrow cell infusions to augment solid organ transplantation, but the outcomes have not b

167 Autoimmune responses to vimentin occur after solid organ transplantation, but their pathogenic effect

168 In the setting of solid-organ transplantation, calcineurin inhibitor (CNI)

169 Women with a history of solid-organ transplantation can be safely offered a wide

170 skin cancer, the most common neoplasia after solid organ transplantation, causes serious morbidity an

171 reviewed for randomized controlled trials in solid organ transplantation comparing an mTOR-I with a n

172 for treatment of cytomegalovirus disease in solid organ transplantation, confirmed genotypic drug re

173 The shortage of deceased donor organs for solid organ transplantation continues to be an ongoing d

174 However, the number of patients awaiting solid organ transplantation continues to remain much hig

175 ients undergoing immunosuppression following solid organ transplantation, contributing substantially

176 Solid organ transplantation creates the ideal medium whe

177 eoplasms occurring in patients who underwent solid organ transplantation, died, and received an autop

178 ldren admitted to the PICU immediately after solid organ transplantation, excluding renal transplanta

179 with PTLD or chronic high viral loads after solid organ transplantation exhibited no homogeneous EBV

180 ressed recrudescent coccidioidomycosis after solid organ transplantation for the large majority of pa

181 lation blockade-based protocol developed for solid organ transplantation for use in stem cell transpl

182 he most common infectious complication after solid organ transplantation, frequently affecting the ga

183 from unrelated donors and in the setting of solid organ transplantation from living donors, the stan

184 tic stem cell transplant cohort and excluded solid-organ transplantation from this cohort.

185 PT-LPD following solid organ transplantation generally occurs in B cells

186 Histocompatibility testing for stem cell and solid organ transplantation has become increasingly comp

187 pplication of bone marrow transplantation in solid organ transplantation has been limited, however, p

188 ytomegalovirus (CMV) disease associated with solid organ transplantation has been modified as a resul

189 Transmission of T. cruzi infection by solid organ transplantation has been reported in Latin A

190 The use of cyclosporine in solid organ transplantation has been shown to be associa

191 Solid organ transplantation has emerged as the standard

192 Although short-term allograft survival after solid organ transplantation has improved during the past

193 d improved immunosuppression, survival after solid organ transplantation has matured to acceptable le

194 h of the experimental and clinical effort in solid-organ transplantation has been directed toward ame

195 nostic biomarkers of acute rejection (AR) in solid organ transplantation have been addressed in multi

196 or and mechanisms of colorectal carcinoma in solid organ transplantation have not been well character

197 Current immunosuppression regimens for solid-organ transplantation have shown disappointing eff

198 tion of immunosuppressive therapy used after solid organ transplantation; however, isolated involveme

199 is used clinically for immunosuppression in solid organ transplantation; however, it is difficult to

200 maglobulinemia (HGG) frequently occurs after solid organ transplantation; however, the prevalence and

201 y present an opportunity for cost savings in solid organ transplantation if equivalent clinical outco

202 After solid organ transplantation, immune-mediated rejection m

203 es on cytomegalovirus (CMV) management after solid organ transplantation in 2010, which provide recom

204 was investigated during the first year after solid organ transplantation in 263 patients who received

205 for over 30 years to pay for deceased donor solid organ transplantation in America.

206 of the oral cavity, which may develop after solid organ transplantation in children.

207 ) continues to be a major complication after solid organ transplantation in high-risk patients.

208 d in the National Institutes of Health (NIH) Solid Organ Transplantation in HIV Trial, reflecting exp

209 liver transplant candidates enrolled in the Solid Organ Transplantation in HIV: Multi-Site Study (HI

210 itis (FCH) has recently been described after solid organ transplantation in patients with hepatitis C

211 es that have resulted in good outcomes after solid organ transplantation in the HIV-positive recipien

212 isk of recurrent or de-novo malignancy after solid-organ transplantation in HIV patients is low.

213 based cohort study of patients who underwent solid-organ transplantation in Ontario, Canada, between

214 Retinal complications of bone marrow and solid organ transplantation include microvascular retino

215 Studies in other solid-organ transplantations indicate that low levels of

216 rnerstone of immunosuppressive therapy after solid organ transplantation, inhibits calcineurin activa

217 Solid organ transplantation is a curative therapy for hu

218 m secondary to infectious aortitis following solid organ transplantation is a rare event that in the

219 Solid organ transplantation is a vital therapy for end s

220 Acute kidney injury after nonrenal solid organ transplantation is associated with prolonged

221 The major impediment to success in solid organ transplantation is chronic rejection (CR).

222 can persist after HC graft rejection even if solid organ transplantation is delayed.

223 Solid organ transplantation is encumbered by an increasi

224 PTLD after solid organ transplantation is frequently EBV-related an

225 The major impediment to long-term success in solid organ transplantation is the development of chroni

226 Solid organ transplantation is the preferred treatment f

227 The field of solid organ transplantation is unique in the breadth of

228 exercise intervention trial after pediatric solid organ transplantation is warranted to determine th

229 he use of generic immunosuppressive drugs in solid organ transplantation is warranted.

230 Cytomegalovirus (CMV) infection in solid-organ transplantation is associated with increased

231 However, their role in solid-organ transplantation is unknown.

232 il (MMF), a widely used immunosuppressant in solid organ transplantation, is a prodrug to deliver myc

233 Tacrolimus, one of the newer agents used in solid-organ transplantation, is gaining increasing popul

234 H1N1 swine influenza could be transmitted by solid organ transplantation led to the publication of gu

235 Severe B-lineage PTLD after solid organ transplantation may be classified as SR or H

236 KIR haplotype B from viral replication after solid organ transplantation may extend beyond CMV to oth

237 n face the highest waiting list mortality in solid-organ transplantation medicine.

238 ert Meeting of the Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Consortium took plac

239 s in ameliorating common complications after solid organ transplantation must be balanced with potent

240 ole in chronic kidney disease after nonrenal solid organ transplantation (NRSOT), although there are

241 In the first meta-analysis, CMV events after solid organ transplantation occurred significantly more

242 Solid organ transplantation offers hope for long-term su

243 tly extrapolated to settings more typical of solid organ transplantation or autoimmunity.

244 promising strategy to induce tolerance after solid-organ transplantation or prevent graft-versus-host

245 ACHE II score (OR, 1.06; 95% CI, 1.01-1.13), solid organ transplantation (OR, 9.50; 95% CI, 2.01-52.2

246 mains an important opportunistic pathogen in solid organ transplantation, particularly in lung transp

247 ngly used off-label as an induction agent in solid organ transplantation, particularly in the setting

248 virus (CMV) remains an important pathogen in solid organ transplantation, particularly lung transplan

249 ing the risk of graft-versus-host disease in solid organ transplantation patients given hematopoietic

250 This study focused on the 107 adult solid organ transplantation patients who were diagnosed

251 and serum samples obtained from nonselected solid-organ transplantation patients suffering from prob

252 a, may support exclusion of pulmonary IFI in solid-organ transplantation patients, the low positive p

253 each individual transplant program, for all solid organ transplantations performed in the United Sta

254 fections may be preventable in the pediatric solid organ transplantation population.

255 information provided through study in other solid-organ transplantation populations than our specifi

256 In solid organ transplantation recipients, exercise is able

257 sive agent that is gaining widespread use in solid organ transplantation recipients.

258 udies have reported EBV(-) PTLD in pediatric solid-organ transplantation recipients.

259 Solid organ transplantation reduces both morbidity and m

260 antigen-1 (LFA-1) blockade to inhibit BM and solid organ transplantation rejection in nonhuman primat

261 elated chain A (MICA) genes are important in solid organ transplantation rejection.

262 ved "passenger" leukocytes in the outcome of solid organ transplantation remains controversial.

263 omplication after hematopoietic stem cell or solid organ transplantation resulting from outgrowth of

264 ains one of the most common infections after solid organ transplantation, resulting in significant mo

265 o be one of the most common infections after solid-organ transplantation, resulting in significant mo

266 The use of calcineurin inhibitors in solid organ transplantation results in an increased risk

267 oing evaluation in autoimmune and allogeneic solid organ transplantation settings, data supporting th

268 In most solid organ transplantation settings, the role of NK cel

269 Graft and patient survival for solid organ transplantations showed improvement over tim

270 eatures and outcomes among a large cohort of solid organ transplantation (SOT) -related patients with

271 l characteristics, and outcomes of SAB after solid organ transplantation (SOT) and compare these feat

272 Immune measurements that distinguish solid organ transplantation (SOT) recipients who control

273 receptors, in regulating the alloresponse to solid organ transplantation (SOT).

274 dity and mortality among patients undergoing solid organ transplantation (SOT).

275 of the net state of immunosuppression after solid organ transplantation (SOT).

276 aematopoieitc cell transplantation (HCT) and solid organ transplantation (SOT).

277 infection is an ongoing clinical problem in solid-organ transplantation (SOT).

278 Incidences may vary among solid organ transplantations (SOTs) and may take to part

279 t represent life-threatening complication of solid-organ transplantation (SOTx).

280 but also as a result of better therapies in solid organ transplantation, stem cell transplantation,

281 gical and infectious challenges accompanying solid organ transplantation, susceptibility to post-tran

282 rfusion injury is an inherent consequence of solid organ transplantation that increases tissue inflam

283 d without hematologic malignancy or previous solid organ transplantation) that were collected for rou

284 In solid organ transplantation, the achievement of an immun

285 s, which are similar to those reported after solid organ transplantation, the patient is satisfied of

286 ) have been implicated in graft rejection in solid organ transplantation, their role in hematopoietic

287 In the setting of solid organ transplantation, there is accumulating evide

288 In solid organ transplantation, there is currently intense

289 lusters of rabies virus transmission through solid organ transplantation, there was a long incubation

290 eight seem to be a persistent problem in all solid-organ transplantation under any form of immunosupp

291 When compared with solid organ transplantation, VCA donation and allocation

292 evention and Management of CMV Disease after Solid Organ Transplantation was published in March 2011.

293 The SMR for cancer death after solid-organ transplantation was higher in children (SMR,

294 Solid-organ transplantation was identified using the nat

295 The relevance of this pathway to solid-organ transplantation was then confirmed by the de

296 ign was used; children in a 23-bed PICU with solid organ transplantation were enrolled into a gown an

297 Unlike solid organ transplantation, which is potentially life-s

298 investigation of how innate immunity impacts solid organ transplantation will likely lead to improved

299 Seventy-four cases of PTLD after solid organ transplantation with sufficient material for

300 ophic virus (HTLV)-1 has been reported after solid-organ transplantation, with a related fatal outcom